Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Target Occupancy PET Study of Xanamem

Next Previous
Trial Profile

A Phase 1 Target Occupancy PET Study of Xanamem

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emestedastat (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics

Most Recent Events

  • 24 Jan 2024 According to an Actinogen Media Release, study results support exploring doses of <-10 mg in clinical trials, consistent with the on-going XanaCIDD (Phase 2a, depression) and XanaMIA (Phase 2b, Alzheimer's disease) trials.
  • 24 Jan 2024 According to an Actinogen Media Release, authors concluded that a dose level of 10 mg daily achieved near saturation of the enzyme target, meaning that higher doses achieved little additional occupancy.
  • 24 Jan 2024 According to an Actinogen Media Release, positive data from this study published in Journal of Alzheimer's Disease.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top